<?xml version="1.0" encoding="UTF-8"?>
<ref id="B216-pathogens-09-00856">
 <label>216.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cao</surname>
    <given-names>Y.F.</given-names>
   </name>
   <name>
    <surname>Tao</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>Y.M.</given-names>
   </name>
   <name>
    <surname>Shi</surname>
    <given-names>C.B.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Chi</surname>
    <given-names>C.P.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>Z.L.</given-names>
   </name>
   <name>
    <surname>Meng</surname>
    <given-names>J.H.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine</article-title>
  <source>Vaccine</source>
  <year>2017</year>
  <volume>35</volume>
  <fpage>5073</fpage>
  <lpage>5080</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.072</pub-id>
  <?supplied-pmid 28803715?>
  <pub-id pub-id-type="pmid">28803715</pub-id>
 </element-citation>
</ref>
